FilingReader Intelligence
Wantai Bio opens account, signs funds supervision agreement
March 17, 2025 at 07:02 AM UTC•By FilingReader AI
Beijing Wantai Biological Pharmacy Enterprise (SSE: 603392) announced the opening of a dedicated settlement account for financial management related to its non-public offering, which raised approximately RMB 3.46 billion after expenses. The offering, approved in 2022, involved the issuance of 25,862,705 new shares at RMB 135.33 per share.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:603392•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Beijing Wantai Biological Pharmacy Enterprise publishes news
Free account required • Unsubscribe anytime